Louisiana State Employees Retirement System Acquires New Position in ICU Medical, Inc. (NASDAQ:ICUI)

Louisiana State Employees Retirement System acquired a new position in ICU Medical, Inc. (NASDAQ:ICUI - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund acquired 10,100 shares of the medical instruments supplier's stock, valued at approximately $1,007,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Private Trust Co. NA increased its holdings in ICU Medical by 1,428.6% in the 3rd quarter. Private Trust Co. NA now owns 321 shares of the medical instruments supplier's stock worth $38,000 after acquiring an additional 300 shares during the last quarter. Boston Trust Walden Corp boosted its holdings in ICU Medical by 6.2% in the 3rd quarter. Boston Trust Walden Corp now owns 267,494 shares of the medical instruments supplier's stock worth $31,834,000 after buying an additional 15,712 shares during the period. Oak Thistle LLC bought a new position in ICU Medical in the 3rd quarter worth approximately $915,000. Xponance Inc. raised its holdings in ICU Medical by 17.8% during the 3rd quarter. Xponance Inc. now owns 2,902 shares of the medical instruments supplier's stock valued at $345,000 after acquiring an additional 439 shares during the period. Finally, Raymond James & Associates boosted its holdings in shares of ICU Medical by 42.5% in the third quarter. Raymond James & Associates now owns 37,720 shares of the medical instruments supplier's stock worth $4,489,000 after acquiring an additional 11,256 shares during the period. 96.10% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, VP Daniel Woolson sold 791 shares of the firm's stock in a transaction dated Friday, March 15th. The shares were sold at an average price of $98.27, for a total value of $77,731.57. Following the completion of the sale, the vice president now directly owns 13,980 shares of the company's stock, valued at approximately $1,373,814.60. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, VP Daniel Woolson sold 791 shares of ICU Medical stock in a transaction that occurred on Friday, March 15th. The stock was sold at an average price of $98.27, for a total transaction of $77,731.57. Following the sale, the vice president now directly owns 13,980 shares in the company, valued at $1,373,814.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Christian B. Voigtlander sold 13,603 shares of the company's stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $107.19, for a total transaction of $1,458,105.57. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,262 shares of company stock valued at $2,545,532. Insiders own 6.70% of the company's stock.

ICU Medical Price Performance

Shares of NASDAQ:ICUI traded down $2.19 on Thursday, hitting $94.53. The company's stock had a trading volume of 147,160 shares, compared to its average volume of 252,730. The company has a debt-to-equity ratio of 0.74, a current ratio of 2.53 and a quick ratio of 1.06. The company has a 50-day simple moving average of $102.07 and a 200 day simple moving average of $98.05. The company has a market capitalization of $2.30 billion, a PE ratio of -76.85 and a beta of 0.69. ICU Medical, Inc. has a 1 year low of $78.28 and a 1 year high of $212.43.

ICU Medical (NASDAQ:ICUI - Get Free Report) last issued its quarterly earnings results on Tuesday, February 27th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts' consensus estimates of $0.85 by $0.39. ICU Medical had a negative net margin of 1.31% and a positive return on equity of 6.35%. The firm had revenue of $587.86 million for the quarter, compared to analyst estimates of $564.77 million. Sell-side analysts forecast that ICU Medical, Inc. will post 3.52 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, KeyCorp raised their target price on ICU Medical from $134.00 to $136.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 28th. One investment analyst has rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $123.00.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.